Synklino ApS

SYNKLINO is founded by Mads Jeppesen, Mette Rosenkilde, and Thomas Kledal. We share a common dream – to transform the life for transplant recipients. We also share a common motivation to develop better drugs while building a sustainable business through global collaborations.

CMV is a severe clinical threat to immunocompromised individuals, such as transplant patients, and is associated with a 100% increase in all-cause mortality risk ratio. Our drug candidate SYNx targets the CMV encoded receptor US28 in lytic and latently infected cells in an outstandingly specific, potent and timely manner. No other drug offerings or strategies in existing pipelines target both lytic and latently infected cells, and no other drug in development provides a similar potential to eradicate CMV.

Initially, SYNx will be developed for patients undergoing solid organ transplantation, preventing late onset CMV disease. This disease currently affects 80% of all D+/R- transplants. Late Onset CMV currently causes suboptimal transplantation outcome, leading to increased morbidity, prolonged hospitalization and raised mortality rates. There is a distinct clinical need for a solution. Development and regulatory requirements allow for small clinical trials, with clear regulatory approval strategies to facilitate drug development.

Contact name:

Thomas Kledal


Frederiksborggade 1, 2. th, 1360 Copenhagen K, Denmark


+45 20121656



Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2019 DANISH BIO – DANSK BIOTEK. All rights reserved.